Inoperable Lung Cancer

                    

The phrase "Inoperable lung cancer" makes a lung cancer diagnosis even quite terrifying. But the cancer inoperable doesn't mean that it can not respond to any other type of lung cancer treatment. 

If any patients have been diagnosed with lung cancer, he'll or she'll surely want to know about several things, including what type of lung cancer I have, what are the treatment options, and about survival rates. And if your doctor has given you words that you have inoperable cancer, literally you’ll want to know about this frightening term as well.

Doctors specifically use the term “inoperable cancer” when they cannot operate with the intent in order to cure the cancer. Here, cancer can not be cured by surgery, rather some other lung cancer treatment options can be effective. 

Why Lung Cancer May Be Inoperable: 

Below mentioned are a few reasons why lung cancer might be termed inoperable:

• Your cancer has spread.
• The location of lung cancer. 
• The health of the patient.

When Inoperable lung cancer spreads to outside your lungs. It’s basically known as unresectable lung cancer.

Types of Inoperable Lung Cancer: 

Inoperable lung cancer basically categorized into two types, based on the size of the affected cells:

Non-small-cell lung cancer (NSCLC): Up to about 85% of lung cancer cases are NSCLC. It has three subtypes:

• Adenocarcinoma
• Squamous cell carcinoma
• Large-cell (undifferentiated) carcinoma.

Small-cell lung cancer (SCLC): This kind of cancer almost occurs due to cigarette smoking. Approximately 70% of cases are usually diagnosed after the cancer has spread. SCLC often grows faster than non-small cell lung cancer, meaning it responds well to radiation therapy and chemotherapy.

Treatment Options: 

In Inoperable lung cancer, you can't have surgery. But it doesn't mean that you can't do anything with your cancer. Several treatment options like radiation therapy, chemotherapy, targeted therapy, and immunotherapy are able to fight it, even when the operation can not be performed. 

Radiation therapy: Your healthcare provider uses high-energy X-rays or other radiation in order to kill cancerous cells or prevent them from growing. Patients with Non-Small Cell Lung Cancer, may direct the energy at a certain part of the body from the outside with the help of a machine (known as external) or implant the radioactive seed, wire, or needle in the body just near the cancer (known as internal). The external radiation therapy is often used for small cell lung cancer.

Chemotherapy: Several medications are able to kill cancerous cells or can prevent from dividing. You may be recommended pills in order to swallow or have injections.

Chemotherapy medications used in order to treat NSCLC. The chemo medications most used for NSCLC include:

• Cisplatin
• Carboplatin
• paclitaxel
• Albumin-bound paclitaxel (nab-paclitaxel, Abraxane)
• Docetaxel (Taxotere)
• Gemcitabine (Gemzar)
• Vinorelbine (Navelbine)
• Etoposide (VP-16)
• Pemetrexed (Alimta)

Targeted therapy: Targeted therapy basically uses medicines or antibodies that are able to attack specific cancerous cells. It leaves comparatively less harm to the healthy cells than either chemo or radiation. It’s mainly recommended for the NSCLC.

Several mutations are able to be treated with targeted therapy medicines. These include:

Tyrosine kinase inhibitors: Tagrisso (osimertinib), Tarceva (erlotinib 150 mg), and Iressa (gefitinib 250 mg), Ofev (nintedanib 150 mg), Gilotrif (afatinib 40 mg), Afinitor (everolimus 10 mg). 

ALK rearrangements: Xalkori (crizotinib), Zykadia (ceritinib), Alectinib (alencensa), and Alunbrig (brigatnib). 

ROS1 rearrangements: Xalkori (crizotinib), Lorbrena (lorlatinib), Rozlytrek (entrectinib), and Zykadia (ceritinib).

Immunotherapy: Immunotherapy is also known as biologic therapy. It helps in order to boost, direct or restore your immune system in order to fight cancer.

Checkpoint inhibitors:

• Atezolizumab (Tecentriq)
• Durvalumab (Imfinzi)
• Nivolumab (Opdivo)
• Pembrolizumab (Keytruda)

Bladder Cancer And Its Treatment

Bladder Cancer: Bladder cancer occurs when the healthy cells in the bladder lining change and grow in an uncontrolled way, forming a mass addressed as a tumor.

Urothelial carcinoma is known as the most common type of bladder cancer.

Squamous cell carcinoma, small cell carcinoma, and adenocarcinoma are often less common types.

Urothelial carcinoma also developed in the ureters, that bring urine from the kidney to the bladder, and responsible for spreading to the kidneys. Bladder cancer can also be described as the non-muscle-invasive or the muscle-invasive. 

Symptoms of Bladder Cancer

In bladder cancer, sometimes doesn’t have many signs or symptoms and is detected when a urine test is performed. Apart from this, most patients with bladder cancer do have some signs and symptoms. 

These symptoms can include:

• Blood in the haematuria 
• Changes in the bladder habits 
• Pain in one side of a lower abdomen or back.

What are the risk factors?

Studies represent that the people with certain risk factors have higher chances to develop bladder cancer. These factors include:

• Smoking
• Older age
• Being male
• Chemical exposure at work
• Chronic infections
• Long-term catheter use
• Previous cancer treatments
• Diabetes treatment
• Personal or family history

How Does Bladder Cancer Start And Spread: Inside the lining of a bladder is the urothelium, which is made of urothelial cells (also called transitional cells). If urothelial cells make the excess copies of themselves and grow out of control, this is a bladder cancer. 

After forming in urothelium, the tumors generally grow into the bladder wall. Then cancerous cells travel through lymph or blood in order to form new tumors in other parts of the body. This is known as metastasis. 

PHASES OF BLADDER CANCER: 

Patients with bladder cancer are grouped into 3 main categories, depending on the stage of cancer. Treatment goals as well as management of these groups are different. 

Non-muscle invasive bladder cancer: Stages 0 and 1 belong to the non–muscle-invasive. It is known as the early bladder cancer. In this, the tumor has not spread to the thick layer of the muscle in the bladder wall. The purpose of treatment for non-muscle-invasive cancer are to: 

• Decrease the risk of cancer coming back after it is being treated successfully. 
• Resist the cancer from progressing to an advanced stage.

Muscle-invasive bladder cancer: Basically stages 2, 3, and early stage 4 are the muscle-invasive. Local control therapy such as radiation or surgery, combined with the chemotherapy, is required in order to prevent the spread of cancerous cells away from the bladder. The purpose of the treatment for muscle-invasive cancer are to:

• Cancer's stage in order to confirm that it is muscle-invasive, but has not metastasized. 
• Determine the best local treatment options. 

Metastatic bladder cancer: In this, the cancer has spread to organs and lymph nodes far from the bladder. These cancers are difficult in order to cure. The major purpose of care for metastatic bladder cancer is to assist you live as comfortably as possible.

Diagnosing of Bladder Cancer: 

Diagnosis is performed with the help of several existing ways:

General Tests: General tests may include:

• blood and urine tests
• an internal examination: in this the healthcare provider slides a gloved finger into the rectum or vagina in order to know for anything unusual. 

Main Tests: In order to diagnose the bladder cancer, your doctor may arrange:

• an ultrasound: a scan that uses soundwaves to create pictures of your organs. 
• a cystoscopy: the doctor inserts a tube with a light and camera through the urethra to view the bladder; a flexible cystoscopy can be done with local anaesthetic, while a rigid cystoscopy is done under general anaesthetic in hospital and may include a biopsy. 
• MRI and CT scans: these basically involve an injection of dye into the body.

Further Tests: In order to check if cancer has spread to other parts of the body, you may have:

• a radioisotope bone scan
• x-rays 
• an FDG-PET scan

Treatment Options For Non-muscle Invasive Bladder Cancer: 

Once tumor found after close examination of the bladder, your doctor may choose to perform a transurethral resection of bladder tumor (TURBT) as a first step in your treatment. 

TURBT: It is generally the initial treatment for non-muscle invasive bladder cancer. It is basically a procedure which is used both for diagnosis as well as treatment. By using this procedure doctors remove the tumor which is generally reserved for the non-aggressive cancer.

Patients with the non-muscle invasive cancer located only in the bladder can be recommended in order to receive immunotherapy or chemotherapy drugs after a TURBT via intravesical therapy. There are numerous intravesical therapy bladder cancer treatment options:

Bacille Calmette-Guerin (BCG): This vaccine is an immunotherapy drug. This therapy is used in order to boost the body’s natural defenses to fight cancer. The onco-BCG is a first-line treatment for carcinoma that has not spread outside the bladder. It is effective in order to prevent bladder cancer recurrences following TURBT.

Mitomycin C: Mitomycin is basically a chemotherapeutic agent used to kill cancer cells. It is mainly given to patients at doctor’s offices, outpatient clinics or hospitals.

The mitomycin injection is easily absorbed into the bladder and has helped with preventing tumor recurrence. 

The mitomycin 40 mg has been used more often immediately after TURBT or sometimes within 24 hours after the initial TURBT treatment.

Thiotepa (Tepadina): Thiotepa is used as intravesical chemotherapy in bladder cancer. The thiotepa is recommended to be used prophylactically in order to prevent seeding of the tumor cells at the cystoscopic biopsy; as a therapeutic agent in order to prevent recurrence after cystoscopic resection of the bladder tumor (transurethral resection of bladder tumor) or as an adjunctive agent at the time of biopsy. 

Cisplatin: The cisplatin 50 mg specifically belongs to the platinum-based antineoplastic family of medications. It works in part by binding to the DNA and inhibiting its replication. 

Intercalating Agents (Doxorubicin, Valrubicin and Epirubicin): These agents are known for good absorption into the bladder, and systemic toxicity is very rare. Doses can vary from 3 times a week to once in a month.

Gemcitabine: This is used for more advanced bladder cancer. In patients who received previous therapy without cure, gemcitabine therapy may be helpful.

Atezolizumab: This medication is used for the locally advanced or metastatic urothelial carcinoma  after the failure of cisplatin-based chemotherapy.

The use of atezolizumab is considered as a first-line treatment for the metastatic bladder cancer in patients who can not receive cisplatin-based chemotherapy and have high levels of PD-L1. 

Laser-Ablation Therapy: This involves using a laser in order to burn cancer cells. Patients for this type of therapy have low-grade papillary tumors as well as a history of the low-grade, low-stage tumors.

List of ovarian cancer medications

Often detected in its later stages when it spreads to the stomach and pelvis, ovarian cancer is the type that occurs in the egg-producing female organs. While most cases do not have any symptom in the early stages, it becomes fatal and complicated to treat during the advanced stage. The very non-specific symptoms include loss of appetite and unusual weight loss. Patients who are experiencing a shift in bowel movement, discomfort in the pelvis area, and frequent urge to urinate need to consult a doctor immediately. 

Medications used for treating Ovarian Cancer

1. Melphalan

Melphalan is single-agent chemotherapy that is prescribed for the treatment of ovarian cancer in adults. It works by destroying the cancer cells and slowing down their further growth in the body. Melphalan 50 mg is given as an intravenous infusion over certain intervals. The dosage can be modified based on the condition of the patient. During the course of treatment, patients must avoid getting pregnant or breastfeeding. It can also interfere with the normal menstrual cycle. The average retail Melphalan price is $675.95, but one can get it at a wholesale rate from several pharmacies. 

2. Gemcitabine hydrochloride

This antineoplastic cytotoxic chemotherapy medication is given in combination with Carboplatin to treat ovarian cancer that has relapsed within 6 months of finishing the last treatment. It is administered intravenously once every 3 to 4 weeks as per the condition of the patient's demands. There are certain moderate side effects like skin rashes, itching, nausea, vomiting, diarrhea, and temporary hair loss that can be managed easily in the gap between two doses where the body is given time to recover.  

3. Carboplatin

It is prescribed in combination with Paclitaxel as an initial treatment of Ovarian Cancer. At this stage, cancer must still be restricted to the ovaries for the treatment to take effect fully. Carboplatin 450mg is infused intravenously once every 4 weeks. The infusion takes about 30 minutes, and then the patient needs to stay back at the hospital for a few hours to let the doctor monitor the immediate after-effects. Usually, 6 cycles of treatment (24 weeks) can yield results, but in certain advanced cases, it can continue longer. The carboplatin price for a single vial of 45mL is 2769 INR.  

4. Olaparib

For the treatment of advanced ovarian cancer, Olaparib is given in combination with other drugs like Bevacizumab to conduct maintenance therapy in patients. It is also effective for patients who have received 2 to 3 lines of chemotherapy prior to this. For refractory conditions, Olaparib is prescribed with Rucaparib to shrink the tumor. The medication is effective in patients where cancer has a specific genetic mutation – BRCA. 

5. Cisplatin

So far, Cisplatin qualifies as the most active drug for the treatment of Ovarian Cancer. It is a chemo drug that is administered intravenously at certain intervals (weeks). To treat advanced conditions, Cisplatin is also given at a high dose in combination with Vinblastine, Ifosfamide, and Etoposide. Before receiving Cisplatin 50 mg, your doctor will provide you with IV fluids for about 8 to 12 hours. For IP chemotherapy, the drug will be injected directly into the abdominal cavity. If you have a hearing impairment and bone marrow suppression, the medication can worsen the conditions. 

6. Niraparib

Patients who have responded fairly to platinum-based chemotherapy can benefit from this medication to slow down the progression rate of ovarian cancer. It is a highly selective oral PARP 1 and PARP 2 inhibitor that is also prescribed as maintenance therapy for recurrent conditions. The dosage for first-line maintenance treatment is determined based on the body weight and platelet count of the patient. For a supply of 100mg 30 capsules, the cost of Niraparib is $7588. 

7. Paclitaxel

It is prescribed in both primary and advanced stages of ovarian cancer. Doctors can also prescribe it with the chemo drug Carboplatin. It is administered as an infusion in the veins. Few patients can have allergic reactions as a result of this. To prevent that, your doctor can prescribe a few medications after transfusion. Paclitaxel 100 mg is given every 3 weeks, but the recent clinical studies show that it had worked more efficiently when the time span was reduced to one week. However, it entirely depends upon the extent of the disease. Paclitaxel price is 5000 INR for a vial of 16.7mL.

Final Words

Ovarian cancer has a better chance of getting completely cured if diagnosed and treated in the initial stages. As it spreads, the chances become slim, and the situation gets deadlier. So far, there have been different drug regimens for the treatment of this condition. Minor side effects are common and can be managed easily since they're not persistent. 

Erlotinib 150 mg medication guide for patients.

Erlotinib is a small molecule medication that inhibits the tyrosine kinase, a kind of enzyme associated with the EGFR (Human Epidermal Growth Factor Receptor).

The drug is indicated for adults and can be prescribed if you have advanced age non-small cell lung cancer. It can also be useful if your previous chemotherapy has not worked to stop your disease.

Erlotinib can also be recommended together with the other treatment named gemcitabine, if you have a cancer of pancreas at the metastatic stage. 

Here are some guidelines for patients who are taking Erlotinib:-

• Your doctor must know about if you are pregnant or plan to become pregnant. It may be harmful to an unborn baby when taken during pregnancy. If you become pregnant use adequate contraception while on treatment, and for at least 14 days after taking the last tablet.

• Erlotinib is known to interact with grapefruit juice so you need to avoid drinking this whilst taking this tablet. Always consume this drug exactly as your doctor has instructed you. 

• The tablet of erlotinib should be consumed at least 1 hour prior to or 2 hours after ingestion of food. The usual dose is 1 tablet of erlotinib 150 mg every day if you have non-small cell lung cancer.

• The usual daily dose is 1 tablet of erlotinib 100 mg, if you have metastatic pancreatic cancer. It is given together with the treatment of gemcitabine. 

• If you take excess erlotinib than you should, contact your pharmacist immediately. You may have increased adverse reactions and your healthcare provider may interrupt your treatment.

• Contact your doctor as soon as possible if you suffer from any side effects. In some cases your healthcare provider may need to reduce your dose of erlotinib or interrupt the treatment. 

• The blood levels can also be impacted by the smoking of cigarettes. Be sure in order to inform your doctor if you're currently smoking, or if you quit smoking while consuming this medicine, as the dose you take may be required to be adjusted.

• Erlotinib 150 mg is available through select specialty wholesalers or pharmacies. The erlotinib price may vary from innovator brand name to generic version. The strip of 10 tablets of Brand name TARCEVA 150 MG Tablets can be grabbed at around ₹35300.

Chronic Lymphocytic Leukemia: Causes, Symptoms, treatments and Medications

Recent stats suggest that out of the total number of Leukemia cases, Chronic Lymphocytic Leukemia or CLL will account for a quarter of it. Most people with this condition live up to 10-20 years after getting diagnosed and getting proper treatment. However, there are some cases where disease progression is rapid, and the patients live only up to a few years. 

Causes of CLL: 

It usually starts due to a certain genetic mutation in the blood-producing cells that leads to the production of ineffective and abnormal lymphocytes. Unlike normal lymphocytes, they don’t die. Instead, they continue multiplying and starts accumulating in the blood and specific organs gradually, which causes complication. The process also interferes with the healthy cells in the bone marrow, and as a result, the production of normal blood cells gets affected. 

The risk factors may include exposure to certain chemicals like herbicides and insecticides. Having a family history of blood or bone marrow cancer may increase your chances too. 

Symptoms

• Swollen glands in the armpits, neck, and groin
• Unusual bruising and bleeding often
• Night sweats
• Shortness of breath and pale skin
• Anaemia 
• Unusual weight loss

These are some of the recognizable symptoms. If you face any of these, it is recommended to contact your healthcare professional and get a checkup done. 

Relation between Chronic Lymphocytic Leukemia and Myeloma 

Both the conditions—Multiple Myeloma and CLL consist of overlapping epidemiologic features. Even though they are seen to be originating from the mature B cells, the chances of these two cases coinciding are quite rare. In Multiple Myeloma, the plasma cells are affected, whereas, in CLL, the lymph nodes, liver and spleen are affected, which ultimately causes the bone marrow to stop functioning. 

Although both CLL and Myeloma are blood cancers, the latter is formed in the bone marrow and responsible for the subset of WBC to form a distinctive protein that causes cancer to grow and spread. They have parallel as well as divergent features. 

The common features include stage-dependent anaemia and immunodeficiency. Not only that, but both diseases respond to alkylating agents. 

Treatment of Chronic Lymphocytic Leukemia 

Although there are different options available, one must also have to keep in mind that there are side effects of each one of them. The upsides and downsides are measured with respect to various medical tests conducted, and then the doctor prescribes which way to go.

1. Radiation Therapy 

If the condition has been diagnosed in a localized stage and the only thing to deal with is an enlarged spleen or swollen lymph nodes, you can opt for low-dose radiation therapy. This treatment of Leukemia is safe and shows much lesser side effects. 

2. Surgery

Also referred to as Splenectomy, one may go with this option to remove the enlarged spleen. However, this is not advisable for an advanced stage condition. 

3. Stem Cell Transplant 

If it is a high-risk condition, stem cell transplant could be considered as an option for early treatment. 

4. Drug Therapy: Chemo and Targeted 

Chemotherapy and targeted therapy are two of the most commonly approached treatment options. The drugs can either be prescribed alone or in combination with other medications to yield the best results. Mention may be made of the following drugs in this respect:

Ibrutinib: It is classified as a Bruton’s Tyrosine Kinase that can inhibit the B-cell lymphoma 2 protein. It is prescribed alone or in combination with Rituximab. The typical dosage for this condition is 420mg per day, i.e., three Ibrutinib 140 mg tablets per day. However, it may be decreased depending upon the extent of the condition and response from the body. 

Alemtuzumab: It has been approved as both first-line and second-line treatment for Chronic Lymphocytic Leukemia. The drug is administered into the body as an injection in the vein. Doctors can prescribe it alone or with Rituximab. This targeted cancer drug can be classified as a monoclonal antibody. 

Venetoclax: It is a B-cell Lymphoma-2 oral inhibitor that is prescribed as a targeted drug alone or in combination with Obinutuzumab and Rituximab. High-risk older patients may also benefit from the combination of Venetoclax and Ibrutinib. The starting dose is 20mg daily for a week, which then ramps up to Venetoclax 100 mg to 400mg per day. The average treatment time is 24 months. 

Obinutuzumab: This is an antineoplastic cytotoxic drug that acts as an anti CD20 monoclonal antibody. It is a chemotherapy drug that is given to the patient as an intravenous infusion through a dedicated line. The B cells have CD20 proteins with which the drug binds to destroy them by engaging the adaptive immune system. 

These are some of the medications that have shown to slow down disease progression in CLL patients and helped to increase the survival rate over the years. Even though there are side effects to this, they are not consistent and easily manageable. 

Conclusion 

Typically, out of 10, 7 patients suffering from CLL have a survival rate of 5 years or more after getting diagnosed. The length of survival time also depends on your overall health condition, medical history and the extent of the disease. If the diagnosed patient has been in a healthy condition for most of their lives, the chances of survival are more for them. The treatment options do not guarantee a surefire cure; they are only for managing the condition and treating the symptoms so that they don’t get worse over time.  

Read:-  Venetoclax for Chronic Lymphocytic Leukemia

Brain Metastases- All you need to know about

What is Brain Metastases: 

As any cancerous tumor grows, cancer cells can break away and be carried to the other organs of the body by the blood or lymphatic system. This is known as metastasis, or metastases when there are so many areas of spread. The metastatic brain tumors basically are the most common brain tumors. 

Although brain metastases may begin due to any kind of cancer, the types that most commonly spread to the brain are as lung, breast and kidney cancers as well as melanoma.

When any new tumor starts spreading to the brain, it isn’t addressed as brain cancer. Rather, it’s named after the area in the body where cancer started. For instance, when lung cancer spreads to the brain is known as metastatic lung cancer.

Symptoms of brain metastases: 

If cancer spreads to the brain may compress the brain and can be responsible for causing swelling inside the skull which leads to the headaches.

Brain metastases may also interrupt the electrical activity of the brain, causing numbness, seizures, tingling or speech problems. When a tumor interrupts the signals from the brain to the muscles, it may result in coordination problems.

Some other reported symptoms areas: personality changes, vomiting, rapid emotional changes, weakness and vision changes. 

What are causes: Brain metastases basically occur when the cancerous cells travel through the bloodstream or the lymph system from the original tumor and spread to the brain. There they may start to multiply. Metastatic cancer spreads from its original location is known as primary cancer. 

There are many theories about what causes some cancers in order to spread and why a few cancers travel to the brain. Brain metastases due to the lung cancer are often detected initial period of the disease, and those due to breast cancer develop late.

What are the risk factors: Any kind of cancer may spread to the brain, but having one of the following types of cancer may put you more likely at the increased risk of brain metastases:

• Lung cancer
• Colon cancer
• Breast cancer
• Kidney cancer
• Melanoma

How are brain metastases detected?

Brain metastases can be detected when the primary cancer is diagnosed. Or, if any patient has symptoms, a healthcare provider may recommend specific tests which basically depends on the symptoms. In order to detect brain metastases, tests may include:

• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI) Scans 

Brain Metastases Treatment Options: 

Metastases breast cancer treatment options for patients with the breast cancer brain metastases as: surgical resection, whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), chemotherapy and targeted therapy. 

1. Surgery: Surgery can be considered as the first treatment for the metastatic brain tumors is tumor removal, or resection. A neurosurgeon: a surgeon who is specially trained in order to operate on the brain and spine will determine if the tumors can be surgically removed by observing patients health as well as status of the disease. 

Some factors which may support surgery including a single tumor larger than the 3 cm, location outside of the speech or motor surrounding areas of the brain, and limited or somewhat stable disease in other organs of the body. Symptomatic tumors can be more likely removed by the surgery. 

2. Chemotherapy: New research indicates that it may be an effective treatment modality for some patients. The use of chemotherapy basically depends on the status of the systemic disease, size of the tumor, primary site and number in the brain, existing medication, and previous history of the chemotherapy treatment, if any. 

• Recent studies demonstrate that a few tumors can be sensitive to drug therapy. SCLC, breast cancer, lymphoma and germ-cell tumors are among these tumors. Some new targeted agents for the metastatic breast cancer (lapatinib 250 mg together with the capecitabine 500 mg), non-small cell lung cancer (EGFR inhibitors, ALK inhibitors) and melanoma (Mek and BRAF inhibitors) are useful for the brain metastases from these particular cancers.
• The emerging existence evidence of the immunotherapy (ipilimumab, pembrolizumab, nivolumab) in patients with brain metastases from the NSCLC and melanoma.
• Intra-CSF chemotherapy (drugs placed within the brain or spine water compartment) may be used for leptomeningeal metastases cancerous cells that metastasize to the covering layers of the brain and spinal cord. 

Chemotherapy breast cancer medication can be combined with other therapies such as radiation. Some tumors that are sensitive to chemotherapy in other parts of the body may become resistant to the chemotherapy once in the brain.

3. Radiation Therapy: Radiation therapy can be used to treat single or multiple brain metastases. It can be used in order to treat a metastatic brain tumor, in order to help prevent the brain metastases in those people who are newly diagnosed with the small-cell lung cancer or acute lymphoblastic leukemia. 

A few types of cancer are quite responsive to the radiation than others. Small-cell lung tumor and germ-cell tumors are highly sensitive to radiation, other types of lung cancer and breast cancers are moderately sensitive, and melanoma and renal-cell carcinoma are less sensitive. 

Medication: High-dose corticosteroids can be used in order to ease the swelling around the tumors and decrease the neurological symptoms. Medications like paclitaxel 100 mg and gefitinib 250 mg also can be recommended for metastases brain tumor. 

Types of Breast Cancer

There are several types of breast cancer. All the breast cancers specifically developed in the breast, so somehow they are alike but can differ in others.

A pathologist studies the tissue removed during a biopsy to learn many things about breast cancer that affect the prognosis (chances of the survival) as well as treatment. A few of these are listed as follows.

Breast cancers mainly can be non-invasive or invasive.

NON-INVASIVE BREAST CANCER:

Non-invasive cancers mainly exist within the milk ducts or lobules in the breast. Non-invasive do not grow into or invade normal tissues within or beyond the breast. Non-invasive cancers often known as the carcinoma in situ (“in the same place”) or pre-cancers. Invasive cancers basically do grow into normal and healthy tissues. 

Ductal carcinoma in situ (DCIS): DCIS is mainly a non-invasive breast cancer (also known as stage 0). With ductal carcinoma in situ, the abnormal cells are presented in the milk ducts of the breast (the tubes that help in order to carry the breast milk to the nipple) and have not spread beyond or into the surrounding breast tissue.

INVASIVE BREAST CANCER: 

These types of breast cancers mainly spread from the original site either the milk ducts or the lobules into the surrounding breast tissue. It can spread to the lymph nodes. The several invasive breast cancer are given as:

1. Lobular carcinoma in situ (LCIS): 

It is basically an overgrowth of the cells that exist inside the lobule. Instead of a true cancer; it is a warning sign of an increased risk for developing invasive cancer in the future in either breast.

2. Invasive ductal carcinoma:

This is also called infiltrating ductal carcinoma, is the most common invasive breast cancer (approximately 50-75 % of all breast cancers). Invasive ductal carcinoma begins in the milk ducts of females breast.

3. Invasive lobular carcinoma: 

Invasive lobular carcinoma is basically the second most common breast cancer (approximately 5-15 % of all the breast cancers). It developed in the lobules of the female breast.

Tubular, colloid and papillary carcinoma and carcinomas with the medullary features are often less common invasive breast cancers.

Special Forms of Invasive Breast Cancer:

1. IBC or Inflammatory Breast Cancer: IBC is a rare as well as aggressive breast cancer. About 1-5 % of all the breast cancers are IBC. 

The main symptoms are as: redness and swelling of the breast, puckering or dimpling of the breast skin and pulling in of the nipple. These symptoms tend to occur very rapidly, over a few weeks or months. Discuss with your healthcare professional if you experience any of the following:

• Swelling of the breast
• Enlargement of the breast. 
• A lump (less common with the IBC than with other breast cancers). 
• Redness of the breast
• Dimpling/puckering of the breast skin 
• Pulling in of the nipple. 
• Breast pain. 

A few symptoms of IBC may be mistaken for a breast infection. It is basically diagnosed after the symptoms which do not improve with the help of antibiotics. If you experience these symptoms and they're longer than the week on antibiotics, tell your physician. Don’t be afraid in order to get a second opinion.

2. Paget disease of the breast: Paget disease is rare cancer in the skin of the nipple or in the skin around the nipple. 

Approximately 1-3 % of the breast cancers are Paget disease of the breast. It usually exists with DCIS or invasive breast cancer. 

Symptoms can be as follows: burning, redness or scaling of the skin on the nipple or areola; a bloody or yellowish discharge from the nipple; and, itching a flattened nipple. Talk to your healthcare professional if you experience any of these symptoms.

3. Phyllodes Tumors of the Breast: Phyllodes tumors are mainly rarest breast tumors that developed in the connective tissue of the breast (stroma) and can grow rapidly in a leaflike pattern. A few of are cancerous, but most are absolutely not.

4. Recurrent or Metastatic Breast Cancer: A returned breast cancer after previous treatment or has spread beyond the breast to other organs of the body is known as recurrent or metastatic breast cancer. 

Bevacizumab together with the paclitaxel (paclitaxel injection) or capecitabine is approved for the first-line treatment of metastatic breast cancer. 

Hormone receptor status: 

All the invasive breast cancers, as well as DCIS, are tested for the hormone (estrogen and progesterone) receptors. 

Hormone receptor-positive (estrogen and progesterone receptor-positive) tumours have many hormone receptors. The treatment of breast cancers can be possible with the help of hormone therapy such as tamoxifen and aromatase inhibitors. Most invasive breast cancers are the hormone receptor-positive.

HER2 status: 

All invasive breast cancers are basically tested for the HER2 protein. 

HER2-positive breast cancers have immense HER2 protein. These breast cancers can be treated with the help of anti-HER2 targeted therapy drugs such as trastuzumab 440mg.

Approximately 10-15 % of the newly diagnosed breast cancers are known as the HER2-positive.

As a second-line treatment, some patients may trastuzumab together with the lapatinib 250 mg. Further treatment may include the combinations of trastuzumab with the other chemotherapy drugs, or together with the lapatinib and capecitabine 500 mg.

Other targeted therapies CDK4/6 inhibitors (palbociclib 125 mg, ribociclib 200 mg and abemaciclib) are also an option for treating the ER positive advanced breast cancer together with an aromatase inhibitor or fulvestrant.

Everolimus tablets together with the exemestane, tamoxifen or fulvestrant is a treatment option for some postmenopausal patients with the ER positive advanced breast cancer which has the progressed after the treatment with a non-steroidal aromatase inhibitor.

Read:- What is Triple Negative Breast cancer